Sharemaestro company-news research for Pfizer Inc. (PFE), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
BUE
Argentina
Provisional evidence
Company news sentiment
Latest PFE news and sentiment
Pfizer Inc.
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
66 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone53/100
→
Published 30-day score51/100
Latest source headline
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
Zacks · 01 Oct 2026 20:45
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
66 current stories are mapped specifically to PFE.
The score uses 7 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.271.
Confidence is 25/100, below the threshold for a firm score.
51/100
News scoreEarly balanced news score
25/100
Confidencethin evidence
79%/100
Company news66 company stories
92/100
Story agreement8/100 difference
News history
Daily score and story count over 30 days
03 Sep18 Sep02 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence5
0.271 after freshness weightingSource breadth100
7 independent publishersCompany relevance79
share tied directly to this companyFreshness55
recency-weighted evidenceAgreement92
how closely stories agreePublisher mix76
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks24 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
03 Apr30 Jun25 Sep
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
25 Sep 202652ARS 11570.0+5.3%
18 Sep 202653ARS 10990.0-0.7%
11 Sep 202655ARS 11070.0-1.6%
04 Sep 202660ARS 11250.0+0.5%
28 Aug 202660ARS 11190.0+0.5%
21 Aug 202658ARS 11130.0+6.0%
14 Aug 202662ARS 10500.0-0.4%
07 Aug 202665ARS 10540.0+6.6%
Provisional evidence
News subjects
What is shaping the score
Market update5025 stories · 38%
Earnings5124 stories · 36%
Capital return466 stories · 9%
Deals and strategy505 stories · 8%
Regulatory and legal522 stories · 3%
Balance sheet502 stories · 3%
Guidance481 stories · 2%
Source mix
Where the evidence comes from
finance.yahoo.com4935 stories · 53%
Simply Wall St.575 stories · 8%
Zacks484 stories · 6%
seekingalpha.com524 stories · 6%
Trefis463 stories · 5%
MT Newswires503 stories · 5%
24/7 Wall St.503 stories · 5%
Recurring subjects
Subjects appearing most often
Pharma34Earnings26Dividends14Oncology13Clinical Trials11Healthcare10Biotech10Fda Approval8Financial Results7Earnings Per Share7
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
01 Aug50 neutral02 Oct 08:01
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 02 Oct 08:01 | 48 | +1 | 33/100 (-1) | 67 (0) | Provisional |
| 01 Oct 23:59 | 47 | -1 | 34/100 (+2) | 67 (+9) | Provisional |
| 30 Sep 23:59 | 48 | -2 | 32/100 (+2) | 58 (-2) | Provisional |
| 29 Sep 23:59 | 50 | +0 | 30/100 (-2) | 60 (+1) | Provisional |
| 28 Sep 23:59 | 50 | +0 | 32/100 (-3) | 59 (+4) | Provisional |
| 27 Sep 23:59 | 50 | -2 | 35/100 (+6) | 55 (+1) | Provisional |
| 26 Sep 23:59 | 52 | +0 | 29/100 (-2) | 54 (-1) | Provisional |
| 25 Sep 23:59 | 52 | +1 | 31/100 (+1) | 55 (0) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 66 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Earnings7 stories
21.5%59.5%
Capital return2 stories
11.2%0.0%
Regulatory and legal1 story
0.0%4.1%
Market update2 stories
0.7%2.9%
Each side uses the same scale: 0–59.5% of the retained directional evidence.
Where the influence comes from
39.2%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
Capital returnNot used in direction
AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September?
Dividend stocks are always great additions to a portfolio, as they offer investors the opportunity to earn passive income during any economic or market environment. This may compensate for weakness in your portfolio during tough market times and supercharge performance during better days …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Dividend stocks are always great additions to a portfolio, as they offer investors the opportunity to earn passive income during any economic or market environment. This may compensate for weakness in your portfolio during tough market times and supercharge performance during better days -- so you'll always be happy to hold onto at least a few of these players. Where to find dividend stocks? They're present throughout industries, but you'll notice many in the healthcare space. Generally, dividend players are well-established companies -- such as some of the world's top pharma names -- that don
- Published
- 22 Sep 2026 10:25
- News subject
- Capital return
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 10.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
DividendsFree Cash FlowHealthcarePharma
—Unscored
EarningsNot used in direction
Update: Pfizer Agrees to Share Incremental Overseas Drug Revenue With HHS
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 21 Sep 2026 17:40
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 10.7d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
EarningsNot used in direction
How Investors Are Reacting To Pfizer (PFE) Easing Policy Pressures And New HHS Revenue-Sharing Deal
Earlier this month, Pfizer's CEO Albert Bourla told investors at Morgan Stanley's Global Healthcare Conference that major headwinds such as tariffs, drug-pricing pressures, declining COVID-19 sales and upcoming patent expiries are beginning to ease, supported by cost actions and a growing…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Earlier this month, Pfizer's CEO Albert Bourla told investors at Morgan Stanley's Global Healthcare Conference that major headwinds such as tariffs, drug-pricing pressures, declining COVID-19 sales and upcoming patent expiries are beginning to ease, supported by cost actions and a growing mix of newer therapies. At the same time, Pfizer's agreement to share a portion of any additional overseas pricing revenue with the U.S. Department of Health and Human Services, alongside management's emphasis on protecting the dividend, offers fresh insight into how the company is balancing policy demands wi
- Published
- 21 Sep 2026 16:14
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 10.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
DividendsDrug PricingEarningsShareholder
—Unscored
EarningsNot used in direction
Huge News For Pfizer Stock Fans
This article first appeared on GuruFocus. Pfizer (NYSE:PFE) will share part of any additional revenue generated from higher drug prices overseas with the U.S. Department of Health and Human Services, according to a Sept. 19 report. The provision is included in Pfizer's most-favored-nation…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article first appeared on GuruFocus. Pfizer (NYSE:PFE) will share part of any additional revenue generated from higher drug prices overseas with the U.S. Department of Health and Human Services, according to a Sept. 19 report. The provision is included in Pfizer's most-favored-nation drug-pricing agreement with the U.S. government and applies to medicines already on the market. The arrangement runs from Jan. 1, 2026, through Jan. 20, 2029, according to documents released by Public Citizen after a Freedom of Information Act lawsuit. Warning! GuruFocus has detected 8 Warning Signs with PFE.
- Published
- 21 Sep 2026 14:40
- News subject
- Earnings
- Why this score
- Legal or regulatory risk
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 10.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Drug PricingHealthcareRegulation
41/100 tone
Capital return
What Would It Take For Pfizer To Cut Its Dividend?
8.6% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
- Published
- 21 Sep 2026 14:17
- News subject
- Capital return
- Why this score
- Dividend reduced
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 36/100
- 30-day weight
- 8.6% of directional evidence · 10.8d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
57/100 tone
[Pfizer sign outside a corporate office building on a sunny day] VIDOK/iStock Unreleased via Getty Images * The US Department of Health and Human Services will get a portion of the increased revenue if Pfizer (PFE [https://seekingalpha.com/symbol/PFE]) is able to charge higher drug prices…
8.9% of directional evidence
Low story strength
Scoring detailsDirect company coverage
[Pfizer sign outside a corporate office building on a sunny day] VIDOK/iStock Unreleased via Getty Images * The US Department of Health and Human Services will get a portion of the increased revenue if Pfizer (PFE [https://seekingalpha.com/symbol/PFE]) is able to charge higher drug prices abroad, according to a media report on Sunday. * The “most favored nation” contract was released on Saturday by the consumer watchdog organization Public Citizen, which obtained it after filing a Freedom of Information Act lawsuit. * The group released documents related to the Pfizer (PFE [https://seekingalph
- Published
- 21 Sep 2026 06:15
- News subject
- Earnings
- Why this score
- Improving financial comparison
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 34/100
- 30-day weight
- 8.9% of directional evidence · 11.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
PharmaPrice TargetRegulation
—Unscored
Market updateNot used in direction
Pfizer Says Its Biggest Headwinds Are Finally Easing. Does That Change the Story for This Ultra-High-Yield Dividend Stock?
The past few years have been challenging for Pfizer (NYSE: PFE). The company has faced macroeconomic problems, significantly lower sales from its coronavirus portfolio, and looming patent cliffs, including for its best-selling drug, the anticoagulant Eliquis. However, according to CEO Alb…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
The past few years have been challenging for Pfizer (NYSE: PFE). The company has faced macroeconomic problems, significantly lower sales from its coronavirus portfolio, and looming patent cliffs, including for its best-selling drug, the anticoagulant Eliquis. However, according to CEO Albert Bourla, Pfizer's headwinds are easing. Is he right?Image source: The Motley Fool. Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a
- Published
- 20 Sep 2026 21:20
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 11.5d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
DividendsEarningsFinancial ResultsOncologyPatent CliffsPharma
57/100 tone
(Bloomberg) -- The US Department of Health and Human Services will get a portion of the increased revenue if Pfizer Inc. is able to charge higher drug prices abroad, according to newly released documents. Most Read from Bloomberg Saudis Give European Oil Buyers No Supplies for Next Month …
12.2% of directional evidence
Low story strength
Scoring detailsDirect company coverage
(Bloomberg) -- The US Department of Health and Human Services will get a portion of the increased revenue if Pfizer Inc. is able to charge higher drug prices abroad, according to newly released documents. Most Read from Bloomberg Saudis Give European Oil Buyers No Supplies for Next Month Zuckerberg Has an AI Empire to Build. Meet the Adviser Who Handles the Details Dubai Gains a Saudi Family Office as Exits From London Grow Air India CEO Weighs Folding Budget Unit Into Group to Cut Costs McDonald's Is Planning to Revamp Its Value Strategy to Revive US Sales The "most favored nation" contract w
- Published
- 19 Sep 2026 21:12
- News subject
- Earnings
- Why this score
- Improving financial comparison
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 34/100
- 30-day weight
- 12.2% of directional evidence · 12.5d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Drug PricingHealthcareTrade Negotiations
—Unscored
Capital returnNot used in direction
Pfizer (PFE), What Is Drawing Fresh Attention Now?
Pfizer (PFE) heads into its Morgan Stanley Global Healthcare Conference presentation on 14 September with investors watching how management frames dividend priorities, recent pipeline setbacks, and the evolving role of newer oncology partnerships. At a share price of US$27.64, Pfizer has …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Pfizer (PFE) heads into its Morgan Stanley Global Healthcare Conference presentation on 14 September with investors watching how management frames dividend priorities, recent pipeline setbacks, and the evolving role of newer oncology partnerships. At a share price of US$27.64, Pfizer has logged a 9.8% year to date share price return and a 22.5% total shareholder return over the past 12 months. This represents a rebound that has built momentum over the last three months as dividend messaging, Q2 guidance revisions, sector strength and fresh oncology deals have shifted how investors are weighing
- Published
- 18 Sep 2026 15:13
- News subject
- Capital return
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Balance SheetDividendsEarningsIntrinsic ValueOncologyPharmaceuticals
—Unscored
EarningsNot used in direction
Pfizer’s Dividend Yield Is Enormous. But Is the Payout Still Growing?
Quick Read Pfizer's 6.20% yield is real and covered by adjusted EPS guidance of $2.80 to $3.00, though its decade-long annual raise streak has stalled at $0.43. Merck raised its quarterly to $0.85 and Bristol-Myers Squibb to $0.63, while Comirnaty and Paxlovid revenue collapses froze Pfiz…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Quick Read Pfizer's 6.20% yield is real and covered by adjusted EPS guidance of $2.80 to $3.00, though its decade-long annual raise streak has stalled at $0.43. Merck raised its quarterly to $0.85 and Bristol-Myers Squibb to $0.63, while Comirnaty and Paxlovid revenue collapses froze Pfizer's payout. CEO Albert Bourla pledged Pfizer will maintain and eventually resume growing the dividend once its loss-of-exclusivity period clears. Read More: Learn 7 secret wealth tips high net worth investors use that most investors miss (sponsor) A 6.20% dividend yield in big pharma usually means one of two
- Published
- 18 Sep 2026 15:06
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
DividendsEarningsPharma
—Unscored
Analyst actionNot used in direction
The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux
For Immediate Release Chicago, IL – September 16 2026 – Zacks.com announces the list of stocks and ETFs featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
For Immediate Release Chicago, IL – September 16 2026 – Zacks.com announces the list of stocks and ETFs featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer PFE, Novartis NVS, Candel Therapeutics CADL and Janux Therapeutics JANX Here are highlights from Wednesday's Analyst Blog: 4 Prostate Cancer Drug Stocks to Watch During Awareness Month September marks Prostate Cancer Awareness Month, putting renewed attention on one of the most common can
- Published
- 16 Sep 2026 09:47
- News subject
- Analyst action
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Clinical TrialsFda ApprovalFourth QuarterPharmaProstate Cancer
—Unscored
Deals and strategyNot used in direction
What Is Pfizer (PFE) Really Getting From Its New ADC Licensing Deal?
Pfizer (NYSE:PFE) has signed a co-development and license deal with Medicus Pharma for an early clinical-stage CD228-targeting antibody-drug conjugate. The agreement grants Medicus exclusive global rights to develop and commercialize the CD228V candidate across multiple human disease area…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Pfizer (NYSE:PFE) has signed a co-development and license deal with Medicus Pharma for an early clinical-stage CD228-targeting antibody-drug conjugate. The agreement grants Medicus exclusive global rights to develop and commercialize the CD228V candidate across multiple human disease areas. Pfizer retains economic participation through financial milestones, royalties and ongoing involvement in the CD228V development program. This new Pfizer Medicus CD228V antibody-drug conjugate partnership is worth weighing against the rest of our findings. Take a look at 4 warning signs we have identified fo
- Published
- 16 Sep 2026 00:19
- News subject
- Deals and strategy
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
BiotechEarningsOncologyPartnershipPharma
—Unscored
Deals and strategyNot used in direction
Pfizer (PFE), Valneva (VALN) Lyme Vaccine Moves to EMA Review Despite Phase 3 Caveat
Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN) reported on August 14 that the European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the companies' experimental Lyme disease vaccine candidate, and will now begin the official review. For a vac…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN) reported on August 14 that the European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the companies' experimental Lyme disease vaccine candidate, and will now begin the official review. For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French biotech Valneva SE (NASDAQ:VALN), this represents the formal transition from years of clinical development into European regulatory review. The Clinical Case The application is based on the Phase 3 VALOR trial,
- Published
- 15 Sep 2026 16:21
- News subject
- Deals and strategy
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Clinical TrialsInstitutional InvestorsPharmaVaccines
—Unscored
Market updateNot used in direction
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK, September 15, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Alexandre de Germay, Chief International Commercial Officer, Executive Vice President, at the J.P. Morgan U.S. All Stars 2026 Confere…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
NEW YORK, September 15, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Alexandre de Germay, Chief International Commercial Officer, Executive Vice President, at the J.P. Morgan U.S. All Stars 2026 Conference on Tuesday, September 22, 2026 at 11:50 a.m. BST. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be mad
- Published
- 15 Sep 2026 14:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
ConferenceFinancial ResultsHealthcarePharma
—Unscored
Market updateNot used in direction
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the past month, shares of this drugmaker have returned +3.2%, compared to the Zacks S&P 500…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the past month, shares of this drugmaker have returned +3.2%, compared to the Zacks S&P 500 composite's -2% change. During this period, the Zacks Large Cap Pharmaceuticals industry, which Pfizer falls in, has lost 0.3%. The key question now is: What could be the stock's future direction? While media releases or rumors about a substantial change in a company's business prospects usually make its stoc
- Published
- 15 Sep 2026 13:00
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Consensus EstimateEarningsEarnings EstimateEarnings GrowthIntrinsic ValuePharmaceuticals
—Unscored
GuidanceNot used in direction
Can Pfizer Overcome Its COVID and Patent Cliff Headwinds?
Pfizer PFE faces a number of structural headwinds, ranging from patent expirations and declining COVID-19 revenues to pricing pressure, intense competition and the need to replenish its pipeline. PFE's LOE Headwinds One of Pfizer's biggest challenges is the approaching loss of exclusivity…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Pfizer PFE faces a number of structural headwinds, ranging from patent expirations and declining COVID-19 revenues to pricing pressure, intense competition and the need to replenish its pipeline. PFE's LOE Headwinds One of Pfizer's biggest challenges is the approaching loss of exclusivity (LOE) for several important products. Pfizer expects a significant negative impact on revenues from the LOE cliff in the 2026-2030 period as several of its key products, including Eliquis, Ibrance, Xeljanz and Xtandi, face patent expirations. The LOE cliff is expected to hurt sales by approximately $1.1 billi
- Published
- 14 Sep 2026 13:37
- News subject
- Guidance
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 17.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsEarnings Per ShareGuidanceOncologyPatent ExpirationPharma
—Unscored
Balance sheetNot used in direction
Pfizer’s 6% Yield Masks a Fragile Dividend Story
Quick Read Pfizer (PFE) pays a 6.19% dividend yield, covered by free cash flow, with CEO Bourla explicitly committing to maintain it even in worst-case scenarios. Comirnaty and Paxlovid revenues collapsed 59% and 63%, leaving replacement drugs still short of fully offsetting Pfizer's lost…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Quick Read Pfizer (PFE) pays a 6.19% dividend yield, covered by free cash flow, with CEO Bourla explicitly committing to maintain it even in worst-case scenarios. Comirnaty and Paxlovid revenues collapsed 59% and 63%, leaving replacement drugs still short of fully offsetting Pfizer's lost COVID-era income. Pfizer carries $60.5 billion in long-term debt against just $976 million in cash, putting debt service and the $2.45 billion quarterly dividend in direct competition. Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Pfizer didn't
- Published
- 14 Sep 2026 13:19
- News subject
- Balance sheet
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 17.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
DebtDividendsEarningsFree Cash FlowPatent CliffPharma
—Unscored
Capital returnNot used in direction
How Concerned Should Income Investors Be About Pfizer's Dividend?
Pfizer (NYSE: PFE) is not hitting on all cylinders today. That's why the stock is down more than 50% from its 2021 high, as of this writing, and its payout ratio is well north of 100%. Dividend investors may find the huge 6% yield attractive, but before buying, you have to ask if that div…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Pfizer (NYSE: PFE) is not hitting on all cylinders today. That's why the stock is down more than 50% from its 2021 high, as of this writing, and its payout ratio is well north of 100%. Dividend investors may find the huge 6% yield attractive, but before buying, you have to ask if that dividend is actually sustainable. The answer is likely yes, here's why. Dividends don't come out of earnings The financial impact of dividends shows up on the cash flow statement, not the earnings statement. This is important to understand as you look at the payout ratio, which compares dividends to earnings. It
- Published
- 12 Sep 2026 18:35
- News subject
- Capital return
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 19.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Balance SheetDividend PaymentsDividendsHealthcarePharma
43/100 tone
2.6% of directional evidence
Low story strength
Scoring detailsDirect company coverage
- Published
- 11 Sep 2026 19:21
- News subject
- Capital return
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 33/100
- 30-day weight
- 2.6% of directional evidence · 20.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
EarningsNot used in direction
Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For?
Photo by Pexels on Pixabay If you hold Pfizer (PFE) or Zoetis (ZTS), you hold the same idea: a branded medicine becomes a standard of care and keeps earning for years, in people or in animals. That is where it stops. Pfizer is buying replacements for older drugs losing exclusivity. Zoetis…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Photo by Pexels on Pixabay If you hold Pfizer (PFE) or Zoetis (ZTS), you hold the same idea: a branded medicine becomes a standard of care and keeps earning for years, in people or in animals. That is where it stops. Pfizer is buying replacements for older drugs losing exclusivity. Zoetis is cutting its effective price to keep the franchises it has. Same bet, two opposite defenses. Which Company Just Raised, And Which One Cut? Pfizer lifted the midpoint of its 2026 revenue guidance by $500 million while cutting its COVID-19 revenue expectation to about $4 billion from about $5 billion. The res
- Published
- 10 Sep 2026 17:05
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 21.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Balance SheetEarningsGrowthOperating IncomePharmaRevenue Growth
—Unscored
Deals and strategyNot used in direction
Medicus Pharma secures Pfizer ADC deal, advances SkinJect and precision oncology strategy
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss a transformative agreement with Pfizer that significantly strengthens the company's position in precision oncology and provides key resources to advance its lead cancer program. Under the development and lic…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss a transformative agreement with Pfizer that significantly strengthens the company's position in precision oncology and provides key resources to advance its lead cancer program. Under the development and licensing agreement, Medicus has secured rights to a CD228-targeted antibody-drug conjugate (ADC) program, while Pfizer is contributing approximately $2 million in development funding, along with inventory and infrastructure support. Bokhari described the transaction as a major milestone that effectively provides
- Published
- 10 Sep 2026 15:58
- News subject
- Deals and strategy
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 21.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
BiotechClinical TrialsFdaOncologyPrecision Oncology
57/100 tone
Pfizer PFE stock has risen 8.6% in the past three months as investors have gained confidence in the company's ability to stabilize earnings and offset the continued decline in COVID-19 product sales. A key catalyst has been a solid second-quarter performance, which showed that higher reve…
2.2% of directional evidence
Low story strength
Scoring detailsDirect company coverage
Pfizer PFE stock has risen 8.6% in the past three months as investors have gained confidence in the company's ability to stabilize earnings and offset the continued decline in COVID-19 product sales. A key catalyst has been a solid second-quarter performance, which showed that higher revenue from non-COVID products more than offset declining sales of its COVID products –Comirnaty (COVID-19 vaccine - in partnership with BioNTech [BNTX]) and Paxlovid (oral antiviral). Excluding sales from BioNTech-partnered Comirnaty and Paxlovid, revenues increased 5% operationally. Pfizer also raised the lower
- Published
- 09 Sep 2026 12:11
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 30/100
- 30-day weight
- 2.2% of directional evidence · 22.9d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Covid 19DividendsEarningsEarnings Per ShareOncologyPatent Cliff
—Unscored
Market updateNot used in direction
Why Pfizer Stock Was so Healthy in August
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 08 Sep 2026 20:54
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 23.5d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
EarningsNot used in direction
Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now
Pfizer (NYSE: PFE) has one of the highest dividend yields of any pharmaceutical stock -- 6.1% at its current share price. That's more than twice the yield that AbbVie (NYSE: ABBV) offers, but in the long run, I believe AbbVie is the better dividend stock. Pfizer has slightly outperformed …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Pfizer (NYSE: PFE) has one of the highest dividend yields of any pharmaceutical stock -- 6.1% at its current share price. That's more than twice the yield that AbbVie (NYSE: ABBV) offers, but in the long run, I believe AbbVie is the better dividend stock. Pfizer has slightly outperformed AbbVie this year, with a return of over 14% compared to more than 12% for AbbVie. However, in terms of revenue growth, AbbVie has grown by more than 138% over the past decade, while Pfizer's revenue is up just over 18% over that period. Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Dou
- Published
- 08 Sep 2026 17:05
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 23.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
DebtDividendsEarningsEarnings Per SharePatent CliffPharma
—Unscored
Market updateNot used in direction
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK, September 08, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, Septem…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
NEW YORK, September 08, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 10:45 a.m. EDT. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web
- Published
- 08 Sep 2026 14:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 23.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
ConferenceFinancial GuidanceFinancial ResultsHealthcare
—Unscored
Deals and strategyNot used in direction
Novartis India acquires Pfizer brands for $132m
Novartis India has agreed to pay Rs12.5bn ($132m) to acquire the Minipres and Minipress trademarks in India, along with certain associated intellectual property rights, from Pfizer and Pfizer Products. The purchase adds an established hypertension brand to Novartis' cardiovascular range. …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Novartis India has agreed to pay Rs12.5bn ($132m) to acquire the Minipres and Minipress trademarks in India, along with certain associated intellectual property rights, from Pfizer and Pfizer Products. The purchase adds an established hypertension brand to Novartis' cardiovascular range. Novartis India's board cleared the deal, after which the company signed an asset purchase agreement and trademark assignment deeds with the two Pfizer entities. The transaction covers trademarks registered in India. In a stock exchange filing, Novartis India said signing and closing would occur at the same tim
- Published
- 08 Sep 2026 08:51
- News subject
- Deals and strategy
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 24.0d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
CardiovascularGrowth RateM APharma
—Unscored
Market updateNot used in direction
This Is What I'd Do With Pfizer Stock Right Now
Investing in a top pharmaceutical company such as Pfizer (NYSE:PFE) might seem like a good long-term hold. Unfortunately, that hasn't been the case in recent years. In the past five years, it has lost close to 40% of its value. Many investors are torn about whether it's a good value buy o…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Investing in a top pharmaceutical company such as Pfizer (NYSE:PFE) might seem like a good long-term hold. Unfortunately, that hasn't been the case in recent years. In the past five years, it has lost close to 40% of its value. Many investors are torn about whether it's a good value buy or just a trap, given the question marks about its long-term future. Here's why I think the stock could be a great buy-and-hold investment right now. Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time
- Published
- 07 Sep 2026 15:50
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 24.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
AcquisitionsDividendsGrowthPharmaShare Price
—Unscored
Market updateNot used in direction
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
The pharmaceutical industry is shifting as legacy blockbusters lose patent protection. Investors must choose between AbbVie Inc (NYSE:ABBV) and Pfizer Inc (NYSE:PFE) as they navigate drug pricing reforms and evolving pipelines. AbbVie has successfully diversified its portfolio beyond its …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
The pharmaceutical industry is shifting as legacy blockbusters lose patent protection. Investors must choose between AbbVie Inc (NYSE:ABBV) and Pfizer Inc (NYSE:PFE) as they navigate drug pricing reforms and evolving pipelines. AbbVie has successfully diversified its portfolio beyond its historic blockbuster Humira, while Pfizer is aggressively deploying capital from its pandemic-era windfall into new oncology and obesity treatments. Both companies are cornerstones of many income-focused portfolios, yet they offer distinct risk profiles for those seeking healthcare exposure. The case for AbbVi
- Published
- 04 Sep 2026 18:50
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 27.6d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Balance SheetDividend PaymentsFda ApprovalFinancial ResultsFree Cash FlowHealthcare
—Unscored
Capital returnNot used in direction
Pfizer’s Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying?
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 04 Sep 2026 13:42
- News subject
- Capital return
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 27.8d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Deals and strategyNot used in direction
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 04 Sep 2026 09:00
- News subject
- Deals and strategy
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 28.0d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
Earlier company news
PFE news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 112 older PFE headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to PFE, but the headline and available text are not mainly about Pfizer Inc.. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of PFE sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.